| Literature DB >> 32275353 |
Livia Marrazzo1, Chiara Arilli1, Roberto Pellegrini2, Pierluigi Bonomo3, Silvia Calusi4, Cinzia Talamonti1,4, Marta Casati1, Antonella Compagnucci1, Lorenzo Livi3,4, Stefania Pallotta1,4.
Abstract
PURPOSE: To develop and validate a robust template for VMAT SBRT of lung lesions, using the multicriterial optimization (MCO) of a commercial treatment planning system.Entities:
Keywords: VMAT; automated planning; lung SBRT; robust templates
Mesh:
Year: 2020 PMID: 32275353 PMCID: PMC7324702 DOI: 10.1002/acm2.12872
Source DB: PubMed Journal: J Appl Clin Med Phys ISSN: 1526-9914 Impact factor: 2.102
Characteristics of patients in the validation set.
| Gender | |
| Male | 12 |
| Female | 8 |
| Age (years) (range) | 66 (38–88) |
| Diagnosed primary tumor | |
| Nonsmall cell lung cancer | 12 |
| Sarcoma | 3 |
| Breast | 2 |
| Kidney | 2 |
| Colon | 1 |
| Tumor location | |
| Left lung | 9 |
| Superior lobe | 7 |
| Inferior lobe | 2 |
| Right lung | 11 |
| Superior lobe | 4 |
| Central lobe | 6 |
| Inferior lobe | 1 |
| Directional tumor position | |
| Posterior | 9 |
| Lateral | 6 |
| Anterior | 5 |
| Average PTV volume (cc) (range) | 30 ± 20 (8.3–77.1) |
PTV, planning target volume.
PTV and OARs requirements for the lung SBRT VMAT plans in five fractions.
| Organ | Constraint | Optimal | Mandatory |
|---|---|---|---|
| PTV | V95% | 100% | ≥98% |
| Dmax (0.1 cm3) | ≤60 Gy | – | |
| Spinal canal (including medulla) | Dmax (0.1 cm3) | <23 Gy | <30Gy |
| D1 cm 3 | <14.5 Gy | – | |
| Esophagus | Dmax (0.5 cm3) | <32 Gy | <34 Gy |
| Heart | Dmax (0.5 cm3) | <27 Gy | <29 Gy |
| Chest wall | D30 cm 3 | <32 Gy | – |
| Normal lungsm(lungs – gross tumor volume) | V20 Gy | – | <10% |
PTV, planning target volume; OARs, organs at risk; VXGy, volume receiving X Gy; DXcm 3, dose to X cm3 of the considered organ.
FIG. 1Flowchart of the stepwise quality improvement model for the development of a class solution for lung SBRT VMAT. A template is created, applied to the first patient of the sample and modified until the produced plan is clinically acceptable. Then the template is applied to the second sample patient: if the resulted plan is clinically acceptable, then the template is applied to further patients. Otherwise it is modified as requested and then applied to further patients (including the first). Mainly the template is optimized by iteratively changing the cost functions or the isoconstraints.
PTV and OARs parameters for MCO auto and clinical manual plans. In bold the P‐values expressing a statistically significant difference between auto and manual plan at the 0.05 level.
| PTV V95% (%) | PTV D0.1 cm 3 (Gy) | GI | PCI | Chest wall V30 Gy (%) | Total lung V20 Gy (%) | Heart D0.5 cm 3 (Gy) | Esophagus D0.5 cm 3 (Gy) |
Cord D0.1 cm 3 (Gy) | Cord D1 cm 3 (Gy) | |
|---|---|---|---|---|---|---|---|---|---|---|
| MCO MFS auto plan (AVG ± 1SD) | 98.1 ± 1.2 | 59.5 ± 0.4 | 5.0 ± 0.6 | 0.83 ± 0.08 | 20.0 ± 12.3 | 5.2 ± 3.0 | 9.7 ± 7.6 | 8.7 ± 5.7 | 8.7 ± 4.5 | 8.0 ± 4.0 |
| MCO HFS auto plan (AVG ± 1SD) | 98.0 ± 2.0 | 59.6 ± 0.4 | 5.0 ± 0.7 | 0.75 ± 0.14 | 21.5 ± 12.5 | 5.4 ± 3.0 | 11.0 ± 8.1 | 9.5 ± 4.5 | 8.7 ± 4.3 | 7.8 ± 4.0 |
|
Clinical plan (AVG ± 1SD) | 97.5 ± 1.9 | 58.7 ± 2.5 | 6.6 ± 1.4 | 0.77 ± 0.12 | 26.4 ± 14.0 | 6.2 ± 3.2 | 11.8 ± 9.3 | 10.4 ± 3.5 | 10.7 ± 4.3 | 9.1 ± 4.1 |
| p MCO MFS vs clinical | 0.3 | 0.1 |
|
|
|
| 0.2 | 0.06 |
| 0.07 |
| p MCO HFS vs clinical | 0.2 | 0.07 |
| 0.7 |
|
| 0.2 | 0.2 |
|
|
MFS, Medium Fluence Smoothing; HFS, High Fluence Smoothing; OARs, organs at risk; PTV, planning target volume; V95%, volume receiving 95% of the prescription isodose; VXGy, volume receiving X Gy; DXcm 3, dose to X cm3 of the considered organ; GI, Gradient Index, volume encompassed by the 50% of the prescription isodose/prescription isodose volume; PCI, Paddick Conformity Index= (target volume in the prescription isodose)2/(target volume × prescription isodose volume).
FIG. 2Comparison between manual, auto MFS, and auto HFS dose distributions. PTV is solid blue. The 100% prescription isodose is red, 95% prescription isodose is orange and 50% prescription isodose is blue. Fifty percent of prescription isodose reveals the large improvement in gradient in the automatic plans. MFS, Medium fluence smoothing; HFS, High fluence smoothing; PTV, planning target volume.
FIG. 3Box plots relative to PTV D0.1cc (a) and Heart D0.5cc (b) for manual, auto MFS, and auto HFS plans. MFS, medium fluence smoothing; HFS, high fluence smoothing; PTV, planning target volume.
Plan complexity parameters and dosimetric verification results for MCO auto and clinical manual plans.
| MCS | Delivery time (s) | MU |
γ passing rate (%) (3%/2 mm, global) | ΔD (%) | |
|---|---|---|---|---|---|
| MCO MFS auto plan (AVG ± 1SD) | 0.29 ± 0.07 | 448 ± 73 | 3379 ± 573 | 91 ± 3 | −1.4 ± 1.4 |
| MCO HFS auto plan (AVG ± 1SD) | 0.40 ± 0.70 | 319 ± 41 | 2368 ± 294 | 96 ± 2 | −0.2 ± 1.7 |
|
Clinical plan (AVG ± 1SD) | 0.37 ± 0.13 | 297 ± 51 | 2146 ± 394 | 96 ± 3 | 0.9 ± 2.0 |
| p MCO MFS vs clinical |
|
|
| 0.3 | 0.06 |
| p MCO HFS vs clinical | 0.7 | 0.2 |
| 1 | 0.59 |
MFS, Medium Fluence Smoothing; HFS, High Fluence Smoothing; volume; MCS, Modulation Complexity Score; MU, Monitor Units; ΔD, percentage dose difference. In bold the P‐values expressing a statistically significant difference between auto and manual plan at the 0.05 level.